Drug
Ruxolitinib Jakafi
Ruxolitinib Jakafi: highest development phase Phase 1, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ruxolitinib Oral Tablet [Jakafi] NCT03110822 | Phase 1 | Multiple Myeloma |
Latest
No recent events.
Follow Ruxolitinib Jakafi on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.